[{"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-001", "question": "A 54-year-old man with metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC) previously treated with platinum-doublet chemotherapy plus pembrolizumab achieves a partial response for 10 months and then develops radiographic progression in lung and liver. Next-generation sequencing on a liver biopsy shows persistent KRAS G12C, a new MET amplification (copy number 9), and no other targetable alterations. PD-L1 TPS is 80%. He is ECOG 1 with adequate organ function. Which of the following is the most appropriate next-line systemic therapy strategy?\n\nA. Switch to docetaxel and ramucirumab\nB. Start adagrasib monotherapy targeting KRAS G12C\nC. Enroll in a clinical trial of KRAS G12C inhibitor plus MET inhibitor combination\nD. Restart pembrolizumab monotherapy at an increased dose\nE. Use carboplatin, paclitaxel, and bevacizumab re-induction", "options": ["Switch to docetaxel and ramucirumab", "Start adagrasib monotherapy targeting KRAS G12C", "Enroll in a clinical trial of KRAS G12C inhibitor plus MET inhibitor combination", "Restart pembrolizumab monotherapy at an increased dose", "Use carboplatin, paclitaxel, and bevacizumab re-induction"], "answer": "C", "answer_index": 2, "explanation": "Emergent MET amplification is a known resistance mechanism to KRAS G12C inhibitors, and early data suggest combined KRAS G12C plus MET blockade may overcome resistance, making a combination clinical trial the most rational choice. Adagrasib monotherapy (B) will likely be undermined by the MET-driven bypass track. Docetaxel/ramucirumab (A) is standard chemo after immunotherapy but ignores a newly actionable resistance pathway in a trial-eligible patient. Pembrolizumab dose escalation (D) and re-induction platinum doublet with bevacizumab (E) are unlikely to benefit after clear progression on prior chemoimmunotherapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include metastatic KRAS G12C-mutant NSCLC with progression after platinum-doublet chemotherapy plus pembrolizumab, persistent KRAS G12C mutation, new MET amplification (copy number 9) on liver biopsy, no other targetable alterations, PD-L1 TPS 80%, ECOG 1, and adequate organ function. These clues point to acquired resistance via MET amplification, making a clinical trial combining KRAS G12C and MET inhibitors the most rational next step to address both drivers. No main logical issues; the item supports a unique best answer without contradictions, underspecification, or multiple defensible options. No main medical accuracy issues; the rationale aligns with current oncology standards, including NCCN guidelines recommending clinical trials for targeted resistance mechanisms in KRAS-mutant NSCLC, and recognizes MET amplification as a bypass resistance pathway to KRAS inhibitors. Early data on combinations like adagrasib plus crizotinib support this approach. Alternatives are appropriately inferior: A is standard second-line chemo but ignores actionable targets; B risks futility due to MET-driven resistance; D lacks evidence for dose escalation; E is nonstandard re-induction. Minimal fix: None needed, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include metastatic KRAS G12C-mutant NSCLC with progression after platinum-doublet chemotherapy plus pembrolizumab, persistent KRAS G12C mutation, new MET amplification (copy number 9) on liver biopsy, no other targetable alterations, PD-L1 TPS 80%, ECOG 1, and adequate organ function. These clues point to acquired resistance via MET amplification, making a clinical trial combining KRAS G12C and MET inhibitors the most rational next step to address both drivers. No main logical issues; the item supports a unique best answer without contradictions, underspecification, or multiple defensible options. No main medical accuracy issues; the rationale aligns with current oncology standards, including NCCN guidelines recommending clinical trials for targeted resistance mechanisms in KRAS-mutant NSCLC, and recognizes MET amplification as a bypass resistance pathway to KRAS inhibitors. Early data on combinations like adagrasib plus crizotinib support this approach. Alternatives are appropriately inferior: A is standard second-line chemo but ignores actionable targets; B risks futility due to MET-driven resistance; D lacks evidence for dose escalation; E is nonstandard re-induction. Minimal fix: None needed, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-002", "question": "A 37-year-old woman develops generalized urticaria, throat tightness, and hypotension within 10 minutes of receiving a first infusion of rituximab for relapsed follicular lymphoma. Symptoms resolve completely with epinephrine, antihistamines, and steroids; tryptase 90 minutes after onset is elevated. Skin testing later shows strong positive intradermal response to rituximab at non-irritating concentrations. She requires anti-CD20 therapy for disease control and has failed obinutuzumab. Which is the most appropriate management of her need for B-cell-depleting therapy?\n\nA. Avoid all monoclonal antibodies and use lenalidomide alone\nB. Perform rapid drug desensitization to rituximab under intensive monitoring\nC. Premedicate with high-dose steroids and retry rituximab at 10% of standard rate without desensitization\nD. Switch to ofatumumab without further allergy evaluation\nE. Use omalizumab for 3 months before rechallenging with rituximab at full dose", "options": ["Avoid all monoclonal antibodies and use lenalidomide alone", "Perform rapid drug desensitization to rituximab under intensive monitoring", "Premedicate with high-dose steroids and retry rituximab at 10% of standard rate without desensitization", "Switch to ofatumumab without further allergy evaluation", "Use omalizumab for 3 months before rechallenging with rituximab at full dose"], "answer": "B", "answer_index": 1, "explanation": "Positive skin testing and elevated tryptase confirm IgE-mediated anaphylaxis to rituximab; the standard of care when the culprit agent is uniquely needed is a rapid desensitization protocol in a specialized setting. Premedication and slow infusion without desensitization (C) is unsafe in IgE-mediated reactions. Cross-reactivity among anti-CD20 mAbs is unpredictable, so empiric switch to ofatumumab (D) risks repeat anaphylaxis. Omalizumab pretreatment (E) is not a substitute for true desensitization. Completely abandoning monoclonals (A) compromises optimal lymphoma care without necessity.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Acute onset of urticaria, throat tightness, and hypotension within 10 minutes of first rituximab infusion, resolved with epinephrine/antihistamines/steroids; elevated tryptase at 90 minutes; positive intradermal skin test to rituximab; relapsed follicular lymphoma requiring anti-CD20 therapy after obinutuzumab failure. These confirm IgE-mediated anaphylaxis and necessitate continued B-cell depletion, making rapid desensitization to rituximab (B) the best option under monitoring.\\nMain logical issue(s), if any: None; stem provides sufficient details for discrimination without contradictions or underspecification, supporting B as uniquely defensible while alternatives are inferior (A suboptimal care; C unsafe without desensitization; D risks cross-reactivity without evaluation; E not standard substitute).\\nMain medical accuracy issue(s), if any: None; aligns with current allergy/immunology guidelines (e.g., AAAAI/ACAAI) for managing IgE-mediated drug hypersensitivity via desensitization when the agent is essential, with accurate rationale on tryptase/skin testing and risks of alternatives.\\nMinimal fix: N/A; item is already unambiguous and accurate, though adding 'per oncology/allergy consultation' to stem could enhance realism without changing intent.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Acute onset of urticaria, throat tightness, and hypotension within 10 minutes of first rituximab infusion, resolved with epinephrine/antihistamines/steroids; elevated tryptase at 90 minutes; positive intradermal skin test to rituximab; relapsed follicular lymphoma requiring anti-CD20 therapy after obinutuzumab failure. These confirm IgE-mediated anaphylaxis and necessitate continued B-cell depletion, making rapid desensitization to rituximab (B) the best option under monitoring.\nMain logical issue(s), if any: None; stem provides sufficient details for discrimination without contradictions or underspecification, supporting B as uniquely defensible while alternatives are inferior (A suboptimal care; C unsafe without desensitization; D risks cross-reactivity without evaluation; E not standard substitute).\nMain medical accuracy issue(s), if any: None; aligns with current allergy/immunology guidelines (e.g., AAAAI/ACAAI) for managing IgE-mediated drug hypersensitivity via desensitization when the agent is essential, with accurate rationale on tryptase/skin testing and risks of alternatives.\nMinimal fix: N/A; item is already unambiguous and accurate, though adding 'per oncology/allergy consultation' to stem could enhance realism without changing intent.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-003", "question": "An 88-year-old woman with frailty (Clinical Frailty Scale 6), CKD stage 3b, and mild Alzheimer disease is hospitalized for community-acquired pneumonia and recovers. She takes amlodipine, sertraline, donepezil, and PRN zolpidem. MMSE is 22/30; she ambulates with a walker and requires help with IADLs but is independent in basic ADLs. Her son asks about starting an intensive multifactorial fall-prevention program including high-dose vitamin D, hip protectors, supervised strength training 5 days/week, and environmental modifications. She has had no falls in the past year. Which recommendation is most appropriate?\n\nA. Recommend the full multifactorial program as requested\nB. Recommend only home environmental modifications and medication review\nC. Start high-dose vitamin D and hip protectors, but avoid exercise\nD. Defer interventions until she has at least one documented fall\nE. Prescribe low-dose benzodiazepine for sleep to reduce nocturnal wandering and falls", "options": ["Recommend the full multifactorial program as requested", "Recommend only home environmental modifications and medication review", "Start high-dose vitamin D and hip protectors, but avoid exercise", "Defer interventions until she has at least one documented fall", "Prescribe low-dose benzodiazepine for sleep to reduce nocturnal wandering and falls"], "answer": "B", "answer_index": 1, "explanation": "In very old, frail adults without a prior fall, targeted interventions-environmental modification and medication optimization-are recommended; high-intensity exercise programs can be burdensome and potentially risky without clear evidence of benefit in this subgroup. High-dose vitamin D (C) has not consistently reduced falls and may increase adverse events. Waiting for a first fall (D) misses the opportunity for primary prevention. Benzodiazepines (E) increase fall and delirium risk. The requested high-frequency supervised strength training (A) is unlikely to be practical or proportionate for her frailty and goals.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 88-year-old frail woman (CFS 6) with CKD 3b, mild Alzheimer (MMSE 22/30), no falls in past year, on medications including PRN zolpidem (fall risk), independent in basic ADLs but needs IADL help, ambulates with walker; son requests intensive multifactorial program (high-dose vitamin D, hip protectors, 5-day/week supervised strength training, environmental modifications). These indicate high fall risk due to frailty, polypharmacy, and dementia, but absence of prior falls supports targeted primary prevention over intensive or deferred approaches. Main logical issue(s), if any: None; stem provides sufficient details for discriminating B as best—targeted, low-burden interventions aligning with risk profile without over-treatment. Main medical accuracy issue(s), if any: Consistent with AGS/USPSTF guidelines emphasizing medication review (e.g., deprescribing zolpidem) and environmental modifications for frail elderly at risk but without falls; high-intensity exercise may be burdensome/risky in CFS 6, high-dose vitamin D lacks strong evidence for fall reduction and may cause hypercalcemia in CKD, benzodiazepines increase falls/delirium, deferring misses prevention opportunity. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 88-year-old frail woman (CFS 6) with CKD 3b, mild Alzheimer (MMSE 22/30), no falls in past year, on medications including PRN zolpidem (fall risk), independent in basic ADLs but needs IADL help, ambulates with walker; son requests intensive multifactorial program (high-dose vitamin D, hip protectors, 5-day/week supervised strength training, environmental modifications). These indicate high fall risk due to frailty, polypharmacy, and dementia, but absence of prior falls supports targeted primary prevention over intensive or deferred approaches. Main logical issue(s), if any: None; stem provides sufficient details for discriminating B as best—targeted, low-burden interventions aligning with risk profile without over-treatment. Main medical accuracy issue(s), if any: Consistent with AGS/USPSTF guidelines emphasizing medication review (e.g., deprescribing zolpidem) and environmental modifications for frail elderly at risk but without falls; high-intensity exercise may be burdensome/risky in CFS 6, high-dose vitamin D lacks strong evidence for fall reduction and may cause hypercalcemia in CKD, benzodiazepines increase falls/delirium, deferring misses prevention opportunity. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-004", "question": "A 62-year-old woman with newly diagnosed metastatic ER-positive, HER2-negative breast cancer involving bone and liver has a germline PALB2 truncating mutation and no BRCA1/2 mutation. She is postmenopausal, has not received prior systemic therapy for metastatic disease, and had adjuvant tamoxifen 15 years ago. ECOG is 0. Liver disease burden is moderate, without imminent organ failure. Which initial systemic treatment strategy is most appropriate?\n\nA. Aromatase inhibitor plus CDK4/6 inhibitor\nB. Single-agent PARP inhibitor targeting PALB2 mutation\nC. Weekly paclitaxel chemotherapy\nD. Fulvestrant monotherapy\nE. Tamoxifen plus ovarian suppression", "options": ["Aromatase inhibitor plus CDK4/6 inhibitor", "Single-agent PARP inhibitor targeting PALB2 mutation", "Weekly paclitaxel chemotherapy", "Fulvestrant monotherapy", "Tamoxifen plus ovarian suppression"], "answer": "A", "answer_index": 0, "explanation": "For first-line metastatic ER+/HER2- disease without visceral crisis, an aromatase inhibitor plus CDK4/6 inhibitor remains standard even in carriers of non-BRCA homologous recombination gene mutations such as PALB2. While PARP inhibitors show activity in PALB2, they are not yet standard first-line outside trials (B). Chemotherapy (C) is reserved for endocrine-refractory or visceral crisis cases. Fulvestrant monotherapy (D) is inferior to CDK4/6-based combinations. Tamoxifen with ovarian suppression (E) is inappropriate in a postmenopausal woman and is less effective than aromatase inhibition.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include ER-positive, HER2-negative metastatic breast cancer in a postmenopausal woman with no prior metastatic therapy, moderate liver involvement without visceral crisis, good ECOG performance status, and germline PALB2 mutation but no BRCA1/2. These support endocrine-based therapy as first-line, specifically aromatase inhibitor (AI) plus CDK4/6 inhibitor, aligning with guidelines like NCCN for avoiding chemotherapy unless refractory or in crisis. The PALB2 mutation does not yet warrant first-line PARP inhibitor outside trials, making A uniquely defensible. No main logical issues; the stem provides sufficient details to discriminate options without contradictions or underspecification. No main medical accuracy issues; the keyed answer and rationale reflect current mainstream standards, where AI + CDK4/6 is preferred over alternatives like PARP (emerging but not standard first-line for PALB2), chemotherapy (reserved for later lines), fulvestrant monotherapy (inferior to combinations), or tamoxifen with ovarian suppression (inappropriate for postmenopausal status). Minimal fix: None needed, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include ER-positive, HER2-negative metastatic breast cancer in a postmenopausal woman with no prior metastatic therapy, moderate liver involvement without visceral crisis, good ECOG performance status, and germline PALB2 mutation but no BRCA1/2. These support endocrine-based therapy as first-line, specifically aromatase inhibitor (AI) plus CDK4/6 inhibitor, aligning with guidelines like NCCN for avoiding chemotherapy unless refractory or in crisis. The PALB2 mutation does not yet warrant first-line PARP inhibitor outside trials, making A uniquely defensible. No main logical issues; the stem provides sufficient details to discriminate options without contradictions or underspecification. No main medical accuracy issues; the keyed answer and rationale reflect current mainstream standards, where AI + CDK4/6 is preferred over alternatives like PARP (emerging but not standard first-line for PALB2), chemotherapy (reserved for later lines), fulvestrant monotherapy (inferior to combinations), or tamoxifen with ovarian suppression (inappropriate for postmenopausal status). Minimal fix: None needed, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-005", "question": "A 29-year-old man has a history of recurrent severe bacterial sinopulmonary infections since childhood, requiring multiple hospitalizations. At age 20 he was diagnosed with common variable immunodeficiency (CVID) based on hypogammaglobulinemia and poor vaccine responses and was started on IVIG, which reduced infections. Over the last 2 years he has developed splenomegaly, autoimmune hemolytic anemia, and noncaseating granulomas on lung biopsy. Lymph node biopsy now shows nodular lymphoid hyperplasia without lymphoma. Flow cytometry reveals near absence of class-switched memory B cells and elevated CD21low B cells. Which underlying mechanistic subtype of CVID best explains his course and complications?\n\nA. Predominantly T-cell signaling defect with normal B-cell maturation\nB. B-cell intrinsic impairment of terminal differentiation and class-switch recombination\nC. Isolated defect of BAFF signaling with expanded naïve B cells\nD. Hyperactive regulatory T cells causing global immunosuppression\nE. Primary phagocyte oxidase deficiency leading to impaired respiratory burst", "options": ["Predominantly T-cell signaling defect with normal B-cell maturation", "B-cell intrinsic impairment of terminal differentiation and class-switch recombination", "Isolated defect of BAFF signaling with expanded naïve B cells", "Hyperactive regulatory T cells causing global immunosuppression", "Primary phagocyte oxidase deficiency leading to impaired respiratory burst"], "answer": "B", "answer_index": 1, "explanation": "CVID patients with absent class-switched memory B cells and increased CD21low B cells have B-cell intrinsic defects in terminal differentiation/class switching and are prone to autoimmunity, granulomatous disease, and lymphoid hyperplasia, matching this case. Predominant T-cell signaling defects (A) generally show more opportunistic infections. BAFF pathway defects (C) usually present with different B-cell phenotypes. Excess Treg activity (D) does not explain the specific B-cell abnormalities. Phagocyte oxidase deficiency (E) characterizes chronic granulomatous disease, not CVID with hypogammaglobulinemia and poor vaccine responses.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent sinopulmonary infections, hypogammaglobulinemia, poor vaccine responses confirming CVID; recent splenomegaly, autoimmune hemolytic anemia, noncaseating granulomas, nodular lymphoid hyperplasia; and flow cytometry showing absent class-switched memory B cells with elevated CD21low B cells. These point to a B-cell intrinsic defect in terminal differentiation and class-switch recombination (option B), associated with autoimmunity, granulomatous disease, and lymphoid proliferation in CVID subtypes. Main logical issue(s): None; the stem provides sufficient discriminating details to identify B as uniquely best, with alternatives clearly inferior (A lacks B-cell phenotype match; C has different B-cell expansion; D doesn't explain specific B abnormalities; E fits CGD, not CVID). Main medical accuracy issue(s): None; aligns with current classifications (e.g., EUROclass) where low switched memory B cells and high CD21low predict complications like autoimmunity and granulomas, consistent with guidelines from AAAAI and ESID. Minimal fix: Not needed, as item is already unambiguous and accurate; if enhancing, add 'per EUROclass criteria' to stem for explicitness.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent sinopulmonary infections, hypogammaglobulinemia, poor vaccine responses confirming CVID; recent splenomegaly, autoimmune hemolytic anemia, noncaseating granulomas, nodular lymphoid hyperplasia; and flow cytometry showing absent class-switched memory B cells with elevated CD21low B cells. These point to a B-cell intrinsic defect in terminal differentiation and class-switch recombination (option B), associated with autoimmunity, granulomatous disease, and lymphoid proliferation in CVID subtypes. Main logical issue(s): None; the stem provides sufficient discriminating details to identify B as uniquely best, with alternatives clearly inferior (A lacks B-cell phenotype match; C has different B-cell expansion; D doesn't explain specific B abnormalities; E fits CGD, not CVID). Main medical accuracy issue(s): None; aligns with current classifications (e.g., EUROclass) where low switched memory B cells and high CD21low predict complications like autoimmunity and granulomas, consistent with guidelines from AAAAI and ESID. Minimal fix: Not needed, as item is already unambiguous and accurate; if enhancing, add 'per EUROclass criteria' to stem for explicitness.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed131-006", "question": "A 91-year-old man with advanced heart failure (EF 25%), CKD stage 4, and severe osteoarthritis lives in a nursing home. He has moderate dementia (MoCA 15/30), needs help with all IADLs and most ADLs, and has had three hospitalizations in 6 months. He has a POLST specifying do-not-resuscitate/do-not-intubate and refusal of ICU care. His daughter, the health care proxy, asks about starting an SGLT2 inhibitor recently recommended by cardiology to reduce heart failure hospitalizations. He has had recurrent genital candidiasis and baseline systolic BPs around 100 mmHg. What is the most appropriate geriatric-focused response?\n\nA. Start the SGLT2 inhibitor because hospitalization reduction is a priority outcome at any life expectancy\nB. Defer the SGLT2 inhibitor due to limited life expectancy, hypotension risk, and alignment with comfort-focused goals\nC. Start the SGLT2 inhibitor at half dose and monitor blood pressure weekly\nD. Replace his loop diuretic with the SGLT2 inhibitor to reduce polypharmacy\nE. Recommend ICU-level monitoring for the first month of SGLT2 therapy", "options": ["Start the SGLT2 inhibitor because hospitalization reduction is a priority outcome at any life expectancy", "Defer the SGLT2 inhibitor due to limited life expectancy, hypotension risk, and alignment with comfort-focused goals", "Start the SGLT2 inhibitor at half dose and monitor blood pressure weekly", "Replace his loop diuretic with the SGLT2 inhibitor to reduce polypharmacy", "Recommend ICU-level monitoring for the first month of SGLT2 therapy"], "answer": "B", "answer_index": 1, "explanation": "In very old, frail patients with advanced multimorbidity, limited life expectancy, and clear preferences against aggressive interventions, guideline-directed therapies with delayed or modest benefit (such as SGLT2 inhibitors) should be reconsidered when risks (hypotension, infections, AKI) and treatment burden outweigh likely gains. Dose reduction (C) does not eliminate these concerns and still adds complexity. Replacing loop diuretics (D) would worsen volume control. ICU monitoring (E) contradicts his POLST. Automatically prioritizing hospitalization reduction (A) ignores his comfort-focused goals and short prognosis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include advanced age (91), frailty (dementia MoCA 15/30, dependent ADLs/IADLs, nursing home), multimorbidity (HF EF 25%, CKD4, osteoarthritis), recent hospitalizations (3 in 6 months), POLST limiting aggressive care (DNR/DNI, no ICU), risks (recurrent candidiasis, SBP ~100 mmHg), and proxy inquiry about SGLT2i for HF hospitalization reduction. These emphasize comfort-focused goals and limited life expectancy, making deferral (B) the best response by aligning with geriatric principles of avoiding burdensome therapies with delayed benefits and high risks (hypotension, infection, AKI). No main logical issues; stem is consistent, supports unique best answer without contradictions or underspecification, as clues discriminate options clearly. No main medical accuracy issues; consistent with current guidelines (e.g., ACC/AHA HF management, AGS deprescribing in frailty), recognizing SGLT2i benefits but prioritizing patient-centered care in advanced illness. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include advanced age (91), frailty (dementia MoCA 15/30, dependent ADLs/IADLs, nursing home), multimorbidity (HF EF 25%, CKD4, osteoarthritis), recent hospitalizations (3 in 6 months), POLST limiting aggressive care (DNR/DNI, no ICU), risks (recurrent candidiasis, SBP ~100 mmHg), and proxy inquiry about SGLT2i for HF hospitalization reduction. These emphasize comfort-focused goals and limited life expectancy, making deferral (B) the best response by aligning with geriatric principles of avoiding burdensome therapies with delayed benefits and high risks (hypotension, infection, AKI). No main logical issues; stem is consistent, supports unique best answer without contradictions or underspecification, as clues discriminate options clearly. No main medical accuracy issues; consistent with current guidelines (e.g., ACC/AHA HF management, AGS deprescribing in frailty), recognizing SGLT2i benefits but prioritizing patient-centered care in advanced illness. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]